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doi:10.1016/j.jpurol.2011.08.012Abstract Objective: To evaluate the effects of exogenous melatonin on the frequency of wet
nights, on the sleep-wake cycle, and on the melatonin profile in children with therapy-
resistant MNE.
Patients and methods: 24 patients were included. Patients had to maintain a diary including
time of sleep and arousal, and whether they had a dry or a wet bed in the morning. We
measured baseline melatonin profiles in saliva. Hereafter, patients were randomized to
synthetic melatonin or placebo. After 3 and 6 months we evaluated the frequency of enuresis
and the melatonin profiles.
Results: 11 patients were randomized to melatonin, 13 to placebo. We evaluated melatonin
profiles of 7 patients in the melatonin group and of 8 in the placebo group. We observed
a change in profile in the melatonin group, but we did not observe a difference in the
sleep-wake cycle or the frequency of wet nights in either group.
Conclusion: This is the first time exogenous melatonin has been evaluated in the treatment of
MNE. Although we observed a change in melatonin profile after the use of exogenous mela-
tonin, we did not observe a change in enuresis frequency or in the sleep-wake cycle of this
select group of patients.
ª 2011 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.c nocturnal enuresis; dDAVP, desamino-D-arginine Vasopressin; AVP, Arginin vasopressin.
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Melatonin treatment in children with therapy 417Introduction
Monosymptomatic nocturnal enuresis (MNE) is a stressful
disorder, both for the individual and on a social level, the
latter mainly by causing stress within the families of
patients.
Besides this, MNE is common: 20% of children in their
first grade experience
MNE [1]. Although the spontaneous cure rate of MNE is
around 15% each year, 1e2% of children stay wet up until
puberty [2,3]. Current therapies for MNE include alarm
treatment, oxybutynin, desamino-D-arginine vasopressin
(dDAVP, desmopressin), tricyclic antidepressants (imipra-
mine) and behavioural techniques, or a combination of
treatments [4,5]. Despite several treatment options, a group
of children remain who do not respond effectively to current
therapies. Long-term cure rates vary greatly and relapse
rates for combination therapy are approximately 20% after 1
year [4,6e11]. For these reasons, other methods of therapy
are worth exploring.
Van Gool et al. postulated a functional relationship
between MNE, age and development of the normal nocturnal
rise in arginine vasopressin (AVP) release with night-time
anti-diuresis, difficulties with arousal from sleep and the 24-
h melatonin profile [12]. The endogenous melatonin cycle is,
amongst other factors, an important regulator of the sleep-
wake cycle in humans [13e15]. This conclusion is acknowl-
edged by several studies about the efficacy of exogenous
melatonin in the treatment of different sleep-wake disor-
ders, and circadian rhythm disorders in blind people
[14e18]. Children with MNE experience difficulties in their
arousal from sleep [19e22], possibly associated with
disturbances of the circadian rhythm. A number of children
with MNE do not have the normal nocturnal rise of endoge-
nous AVP, which is associated with circadian melatonin
excretion [12]. Furthermore circadian melatonin excretion
is age-dependent: highest levels are found in the age range
of 1e5 years. Just before puberty, melatonin levels decline
and stay low with increasing age [23,24]. Several studies
show that exogenous melatonin is able to shift the sleep-
wake cycle: 1e2 h forwards when taken at dusk, 1 h back-
wards when taken at dawn [18,25e27]. Considering these
observations and previous comments, exogenous melatonin
may have a therapeutic function in the treatment of MNE. To
our knowledge, exogenous melatonin has not yet been
reported as a treatment option in MNE.
The aim of this study was to evaluate the effects of
exogenous melatonin on the frequency of wet nights, on
the sleep-wake cycle, and on melatonin profiles in children
with therapy-resistant MNE.
Patients and methods
The design of the study was a randomized placebo-
controlled double trial aiming to include 90 patients
between 10 and 16 years of age with therapy-resistant MNE.
Patients were enlisted during a period of 2 years in a single-
center setting. To be eligible for inclusion, patients had to
experience a minimum of 2 wet nights weekly. At the time
of inclusion no patient used any drug that could influence
the MNE. All patients had a clinical evaluation whichincluded medical history and voiding history, physical
examination, ultrasonography of kidneys and bladder,
urinalysis, and uroflowmetry with ultrasound residual
volume measurement.
Patients who had received a positive long-term effect
from any medication were excluded, as well as patients with
a history of urinary tract infections. MNE was defined as
a normal void occurring at an inappropriate and socially
unacceptable timeand place, in this case at night in bed [28].
Informed consent was obtained from patients and their
parents.
Before randomization, all patients were asked to keep
a nocturnal enuresis diary for at least 2 weeks, including
time of sleep and time of arousal, and whether they had
a dry or wet bed in the morning. Additionally, a melatonin
profile was measured in saliva samples [29]: every 2 h, from
6 pm until 8 am, patients had to chew on a cotton plug for
1 min. The samples were collected under dim light while
the patients were sleeping in the dark. Hereafter, the
samples were kept unexposed to light, wrapped in
aluminium foil, and were frozen and sent to the laboratory.
Melatonin levels were measured using a radioimmunoassay
method (Buhlmann Laboratories AG, Switzerland). Mela-
tonin in saliva was expressed as pg/ml. The detection limit
of the assay was 0.5 pg/ml for each sample [29]. The
melatonin rhythm in saliva has the same time curve as in
serum with no delay [29e31].
After baseline measurements, children were randomly
assigned to 3 months of 5 mg synthetic melatonin orally or
placebo, to take at 8 pm daily. The dose of melatonin was
based on findings described in a review of several studies by
Jan et al. [14].
After randomization, children had to keep a nocturnal
enuresis diary, with help from their parents, for another 6
months. After 3 and 6 months another melatonin profile
was measured with salivary samples using the same
procedure as before randomization. The primary outcome
variable was the frequency of wet nights as this was
considered the most clinically relevant measure of effi-
cacy. Secondary outcomes were sleep-wake rhythm,
melatonin profile and quality of life within the family of
the patient. We considered children with a reduction of
90% or more in frequency of wet nights as responders,
a reduction of 50% as partial responders and less than 50%
as non-responders. We planned for 90 patients to be
included, 45 in each arm. Assuming a 5% response rate in
the placebo group, this number is sufficient to demonstrate
an absolute difference in response rate between the
randomized groups of 25% or more with 80% power (1-beta)
and alpha 0.05. In the event, we included considerable
fewer patients than planned. The study was stopped
because no positive response with regard to bedwetting
was found in either group. Therefore, we restricted our
statistical analyses to the continuous variables as these are
generally associated with more statistical power. Conse-
quently, we analyzed the difference between the
randomized groups in change in the frequency of wet
nights and levels of melatonin from baseline to 3 months
and 6 months of follow-up using analysis of covariance. We
refrained from analysis of the 6-month measurements of
melatonin levels as, by that time, the missing rate for
melatonin measurements was 40%.






No. of wet nights at baseline
(per week), mean  SD
6.41  1.32 5.11  1.46
No. of wet nights at 3-month
follow-up (per week),
mean  SD





No. of wet nights at 6-month
follow-up (per week),
mean  SD





Responders, n 0 0
Partial responders, n 0 1
Difficulties with arousal, n 11 13
a Difference (95% confidence interval) between treatment
groups adjusted for baseline value.
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All patients with therapy-resistant MNE were screened and,
if possible, included. After inclusion of 24 patients, we had
to end the study and broke the randomization code because
of excessively slow inclusion and therapeutic failure. By
that time, 11 patients were randomized to melatonin, and
13 to placebo. Of the included patients, 3 (12.5%) were
girls, 1 in the melatonin and 2 in the placebo group. Patient
characteristics are shown in Table 1. The mean weekly
number of wet nights before start of the treatment was not
substantially different between the melatonin and the
placebo group indicating successful randomization (Table
2). For 5 patients in the melatonin group we managed to
retrieve a full melatonin profile, consisting of a profile
before randomization, one 3 months after start of medi-
cation and one 6 months after randomization. For 2
patients we could only obtain a partial profile, but enough
to determine the effect of melatonin after 3 months. In the
placebo group we managed to retrieve 7 full melatonin
profiles and 1 partial profile. In the melatonin group, we
observed a shift in profile after 3 months of medication: the
mean melatonin level peaked 4 h earlier after the use of
melatonin (Fig. 1). In the placebo group we observed no
difference between the mean baseline melatonin profile
and the curves after 3 months (Fig. 2). The mean level of
the curve after 3 months was higher in the melatonin than
in the placebo group although this difference was not
statistically significant (Table 3). Although we observed
a change in melatonin levels in saliva after the use of
melatonin, we did not observe a significant change in the
frequency of wet nights after the use of melatonin (Table
2). No side-effects of melatonin use were mentioned.
Discussion
MNE is caused by a combination of pathogenic factors, such
as small functional bladder capacity, difficulties with
arousal from sleep and nocturnal polyuria [19e22,32,33].
Of children with nocturnal enuresis, 41%e90% have good
short-term results with an enuresis alarm, different training
modalities, desmopressin, oxybutinin, tricyclic anti-
depressives or a combination. Unfortunately the relapse
rate of these therapies is significant [7e11]. Most of our
patients had a smaller functional voided volume than one
would expect according to age (Table 1). All patients in this





Age, mean  SD, years 12.03  1.38 13.32  1.81
Male gender, n 10 11
Weight, kg (mean) 43.5  12.14 51.5  11.23
BMI, kg/m2 17.86  2.93 19.48  3.42
Max. measured bladder
volume (mean)
213.54  101.3 292.76  3.42
< 75% functional bladder
capacity, n
9 8threshold and had proven to be resistant to the treatment
options mentioned above. In the outpatient clinic, the
history of MNE patients often shows a link between diffi-
culties in arousal, enuresis and the sleep-wake cycle: when
patients travel across different time zones westward,
inducing a cycle change, the MNE can stop for several
months. Furthermore, when patients stay over with friends
or family the wet night frequency can decrease, possibly
due to a more superficial sleep [12].
The pineal gland hormone melatonin, the rhythm of
which is controlled by the suprachiasmatic nuclei, is known
to give the body information about the time of day and
possibly, because secreted at night, it reinforces darkness-















before medication 3 months after start medication
Figure 1 Mean saliva melatonin profile in melatonin group.
We observed a shift in melatonin profile as well as a change in
height of the curve after 3 months.
























before medication 3 months after start medication
Figure 2 Mean saliva melatonin profile in placebo group.
After 3 months, neither a shift in melatonin profile occurred,
nor a change in height of the curve.
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[15,35]. Circadian rhythm seems not only important for the
sleep-wake cycle, but also it may have its effects on other
circadian rhythms, like the release of endogenous AVP.
Rittig et al. [36] described abnormal circadian AVP levels in
MNE patients compared to non-enuretic controls, which
resulted in symptomatic treatment of MNE with desmo-
pressin [9,36].
Melatonin concentrations are low in the daytime, rising
at around 10.00 pm to peak at 02.00e03.00 pm, and
declining back to baseline in the morning [34]. The increase
of melatonin seems to coincide with the moment of urine
loss in MNE patients, which could imply a relationship
between increase of sleep arousal threshold and bed-
wetting [37]. Although our groups were small and levels of
melatonin differed between patients, we observed the
same baseline melatonin rhythm as described. These find-
ings are confirmed by Ardura-Fernandez et al., who
compared melatonin levels in saliva between enuretic
patients and controls [37]. Another report showed no
differences in endogenous production of melatonin
between children with MNE and controls [38]. It is knownTable 3 Changes in maximum levels of melatonin (M max)
and peak-Time (T) from baseline (T max 0) to 3 months of





Mean  SD M max 0
(pg/ml)
20.7  10.3 22.0  10.1
Mean  SD M max 3
(pg/ml)
32.0  18.1 22.6  8.0
Group differencea 12.2 (3.1; 27.4)
Mean T max 0 (24 h) 2.00 2.00
Mean T max 3 (24 h) 22.00 2.00
% shift of curveb 71.4% 25%
a Corrected for baseline values using analysis of covariance
(95% confidence interval).
b Percentage of patients with time shift of melatonin peak to
an earlier hour.that exogenous melatonin can shift the phase of the sleep-
wake cycle forward when taken before sleep-time at night
[18,25e27]. Van Gool et al. mentioned the possibility of
manipulation of the 24-h melatonin profile with exogenous
melatonin and the possible effect on enuresis in children
with MNE [12]. We tested this theory by randomizing
patients to melatonin and placebo before they went to
sleep. Although we observed a shift in peak-time and height
of the melatonin profile in the group who received mela-
tonin (Fig. 1), we did not observe a change in sleep-wake
cycle. Also, the ability of patients to wake up from sleep
did not seem to be influenced by exogenous melatonin, as
parents still reported difficulties in arousal.
When we looked at frequency of wet nights, we did not
observe a difference in either group, although one patient
in the control group improved significantly, possibly
because of a change from summer to winter time (Table 2).
This lack of positive effect on enuresis could explain why
a lot of our patients were not motivated to collect their
salivary melatonin samples in the correct way after 3 and 6
months.Conclusions
To our knowledge, this is the first time exogenous melatonin
has been evaluated in the treatment of MNE. Although we
observed a change in level and peak-time of melatonin in
saliva after the use of melatonin, we did not observe
a significant change inenuresis frequency, nor didweobserve
a change in sleep-wake cycle. Therefore, we conclude that
the role of melatonin in the treatment of therapy-resistant
MNE is limited. However, the studied population was rela-
tively small and consisted of a select group of patients
resistant to all other forms of therapy. Further studies are
necessary to explore new treatment options for this difficult
group of patients.Funding
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